TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Compare the Oncological Benefit of Deep Neuromuscular Block in Gastric Cancer Obesity Patient

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Gastric cancer patients with laparoscopic subtotal gastrectomy~* 19-75 years~* Body mass index(BMI) \> 25kg/m2~* American Society of Anesthesiologists I-III~Exclusion Criteria:~* American Society of Anesthesiologists Class IV~* End stage renal disease (ESRD) patient~* Patients with allergy to muscle relaxants~* Patients with diseases that may affect muscle relaxation

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Deep neuromuscular block group (Type: EXPERIMENTAL): Sugammadex sodium 4mg/kg/IV after operation
- Moderate neuromuscular group (Type: EXPERIMENTAL): Sugammadex sodium 2mg/kg/IV after operation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Iressa Versus Docetaxel (Taxotere)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Measurable (uni dimensional) disease by RECIST criteria in a lesion not previously irradiated or non measurable disease~* Locally advanced or metastatic NSCLC, not amenable to curative surgery or radiotherapy~* Advanced non-small cell lung cancer (NSCLC) that has recurred or progressed after receiving prior treatment with platinum-based chemotherapy~* WHO performance status (PS) 0-2~* Absolute Neutrophil Count (ANC) \>1.5 x 109/liter (L) and platelets \>100 x 109/L~* Life expectancy of at least 8 weeks~Exclusion Criteria:~* Prior ZD1839 therapy~* Prior docetaxel treatment for NSCLC~* Less than 14 days since completion of prior radiotherapy~* Less than 21 days since prior chemotherapy, immunotherapy or biological systemic anticancer therapy~* Evidence of clinically active Interstitial Lung Disease~* Other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ~* Newly diagnosed CNS metastases that have not yet been treated with surgery and/or radiation. Patients with previously diagnosed and treated CNS metastases or spinal cord compression may be considered if they have evidence of clinically SD (no steroid therapy or steroid dose being tapered) for at least 28 days~* Patients with pre existing peripheral neuropathy \>= grade 2 (NCI CTC criteria)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Radiation Therapy and Temozolomide Followed by Temozolomide and Poly ICLC in Treating Patients With Newly Diagnosed GBM

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed supratentorial grade IV astrocytoma (glioblastoma multiforme) by biopsy or resection within the past 3 months~PATIENT CHARACTERISTICS:~* Karnofsky performance status ≥ 60%~* Absolute neutrophil count ≥ 1500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Bilirubin ≤ 1.5 mg/dL~* Transaminases ≤ 4 times above the upper limits of the institutional normal~* Creatinine ≤ 1.7 mg/dL~* Not pregnant or breast-feeding~* Patients must agree to follow acceptable birth control methods to avoid conception~* Negative pregnancy test~* Patients must have a Mini Mental State Exam score of ≥ 15~* No serious concurrent infection or medical illness which would jeopardize the ability of the patient to receive the treatment outlined in this protocol with reasonable safety~* Patients with a concurrent or prior malignancy are ineligible unless they are patients with curatively treated carcinoma-in-situ or basal cell carcinoma of the skin~  * Patients who have been free of disease (any prior malignancy) for ≥ five years are eligible for this study~* Patients requiring ongoing therapy for psychoses with antipsychotic medications at the time of enrollment will be ineligible~PRIOR CONCURRENT THERAPY:~* Patients must not have received prior radiation therapy, chemotherapy, immunotherapy or therapy with biologic agent (including immunotoxins, immunoconjugates, antisense, peptide receptor antagonists, interferons, interleukins, TIL, LAK or gene therapy), or hormonal therapy for their brain tumor~  * Prior glucocorticoid therapy is allowed~* Patients must be willing to forego other cytotoxic and non-cytotoxic drug therapy against the tumor while being treated with poly ICLC plus temozolomide on this protocol~* No other concurrent therapy for their tumor (i.e., chemotherapeutics or investigational agents)~* Patients who have received prior Gliadel wafers are not eligible for this study~* No concurrent prophylactic filgrastim (G-CSF)~* No concurrent electron, particle, implant, or stereotactic radiosurgery boost

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Treatment Arm (Type: EXPERIMENTAL): RT + TMZ 6wks, followed by~poly ICLC, temozolomide, radiation: radiation therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Imatinib Mesylate With or Without Interferon Alfa or Cytarabine Compared With Interferon Alfa Followed by Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Newly diagnosed chronic phase chronic myelogenous leukemia (CML)~  * bcr-abl positive~ * No blasts, promyelocytes, myelocytes, or metamyelocytes in the peripheral blood~* Availability of a HLA-identical sibling or unrelated donor~PATIENT CHARACTERISTICS:~Age~* Any age~Performance status~* Not specified~Life expectancy~* Not specified~Hematopoietic~* Not specified~Hepatic~* Not specified~Renal~* Not specified~Other~* Not pregnant or nursing~* Fertile patients must use effective contraception~* No second malignancy requiring therapy~* No evidence of disease-related symptoms or extramedullary disease (including hepatosplenomegaly)~* No serious diseases that would preclude study participation~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No prior interferon~Chemotherapy~* No prior chemotherapy other than hydroxyurea~Endocrine therapy~* Not specified~Radiotherapy~* No prior radiotherapy~Surgery~* Not specified~Other~* Prior anagrelide allowed~* No participation in another clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of the Efficacy/Safety of Symbicort® Turbuhaler®,Seretide™ Diskus™ 50/500 µg & Terbutaline Turbuhaler® 0.4 mg

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with asthma since at least 6 months prior to first visit~* Prescribed daily use of glucocorticosteroids for at least 3 months prior to first visit~* At least one asthma exacerbation more than one but less than twelve months prior to first visit~Exclusion Criteria:~* Respiratory infection affecting asthma within 30 days before first visit~* Use of oral, rectal, or parenteral glucocorticosteroids for within 30 days before first visit~* Any significant disease or disorder that may jeopardize the safety of the patient~Additional inclusion and exclusion criteria will be evaluated by the Investigator.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Incidence And Outcome Of Paracentesis Induced Circulatory Dysfunction In Acute-On-Chronic Liver Failure.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. All patients with acute hepatic insult manifesting as jaundice (Sr. Bil. ≥ 5 mg/dL) and coagulopathy (INR≥1.5), complicated within 4 weeks by ascites and/or encephalopathy in a patient with previously diagnosed or undiagnosed chronic liver disease (ACLF) admitted in the hospital.~2. All Cirrhotics decompensated with ascites admitted in the hospital.~3. Grade II/III ascites~4. Need for paracentesis.~Exclusion Criteria:~1. Age \<12 or \> 75 years~2. Hepatocellular carcinoma~3. Non cirrhotic ascites such as malignancy or tubercular peritonitis~4. Serum Cr \>1.5mg%~5. Refractory septic shock~6. Grade III/IV hepatic encephalopathy~7. Abdominal wall cellulitis~8. Active variceal bleed~9. Respiratory, cardiac and renal failure~10. Refusal to participate in the study

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Albumin (Type: EXPERIMENTAL): MVP (Modest Volume Paracentesis) of less than 5 litres with intravenous albumin at a dose 8 gms/l of ascitic fluid.
- No Albumin (Type: ACTIVE_COMPARATOR): MVP (Modest Volume Paracentesis) of less than 5 litres without albumin.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Platelet Function in Diabetic Patients With and Without Renal Impairment, and the Effects of Lipid Lowering Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diabetes mellitus type 1 or type 2~* With or without established microalbuminuria (albumin-to-creatinine ratio (ACR)2,5-25 mg/mmol for men, and 3,5-25 mg/mmol for women, according to ISH and ESC recommended criteria)~* Glomerular filtration rate (GFR) between 15-60 ml/min/1.73m2 (measured the last 6 months) or GFR \>75ml/min/1.73m2. The abbreviated Modification of Diet in Renal Disease (MDRD) equation will be used to calculate GFR.~* Age 18-80 years~Exclusion Criteria:~* Definite history of myocardial infarction, coronary revascularisation procedure or stroke. (i.e, a strong clinical indication for statin treatment)~* Functioning renal transplant, or living donor-related transplant planned.~* Patients on dialysis.~* Poor metabolic control, i.e HbA1c \> 9%~* Definite history of chronic liver disease, or abnormal liver function (i.e ALT \>1,5 x ULN or, if ALT not available, AST \> 1,5 x ULN).~* Evidence of active inflammatory muscle disease (e.g dermatomyositis, polymyositis), or CK\>3 x ULN;~* Definite previous adverse reaction to a statin or to ezetimibe~* Definite previous adverse reaction to acetylsalicylic acid.~* Definite previous adverse reaction to an ACE-inhibitor.~* Need for concomitant treatment with a strong inhibitor of CYP3A4, such as itrokonazole, ketokonazole, erythromycin, clarithromycin, HIV-protease inhibitors or nefazodone (i.e. agents that may markedly elevate simvastatin levels).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- simvastatin + ezetimibe (Type: EXPERIMENTAL): Cross-over study with placebo only run-in period. All patients participate in this arm with simvastatin + ezetimibe either as first treatment period (8-10 weeks)or second treatment period (8-10 weeks). The primary comparison is ezetimibe vs. placebo on top of simvastatin. A secondary comparison will be simvastatin vs. placebo run-in.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Polytraumatisms With Corticoids

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age superior of 15 years~* Hospitalization in reanimation for polytraumatism (lesion of two organs with a vital risk)~* SISS score more than 15~* Intubation for more than 48 hours.~* Agreement of a family member~* Patient with insurance~Exclusion Criteria:~* History of corticothérapies within 6 months~* History of adrenocortical insufficiency.~* Treatment by immunosuppressor~* Immunodeficiency.

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- H (Type: EXPERIMENTAL): Hydrocortisone
- P (Type: PLACEBO_COMPARATOR): Treatment by NaCl (placebo)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Health Promotion on Allergic Rhinitis by Infrared-C Ray Irradiation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults that age 20 above and 50 below~* Clinical diagnosis confirmed as allergic rhinitis~* Conscious, no mental or cognitive impairment~* Able to read, write or communicate in Mandarin, Taiwanese or Hakka, and agreed to participate~Exclusion Criteria:~* Inflammatory skin wounds on the back of the shoulder, neck or lower back~* Polyposis~* Acute and chronic sinusitis~* Vasomotor rhinitis

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- experimental group (Type: EXPERIMENTAL): Received infrared-C ray irradiation by hot compress with a powered heating compress and an eye mask for 40 minutes/time/day Treated regions: eyes and nose region, back region of head, shoulder neck and low back.~Received medical treatment, e.g., Xyzal Oral Product and Fluticasone Furoate.
- Control group (Type: PLACEBO_COMPARATOR): received only medical treatment, e.g., Xyzal Oral Product and Fluticasone Furoate.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI362 in Overweight or Obesity Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Have stable body weight for the past 12 weeks prior to screening~2. Have a body mass index (BMI) ≥24 kilograms per meter squared (kg/m²) with complication, or BMI≥28 kg/m²,inclusive at screening~3. Willing and agreeable to commit to the duration of the study and undergo study procedures as instructed by the clinic staff~Exclusion Criteria:~1. Have a diagnosis of type 2 diabetes~2. Have received prescription drugs or over the counter drugs that promote weight loss in the past 3 months prior to screening~3. Previous treatment with a GLP-1 (glucagon-like peptide 1) receptor agonists or GCG(glucagon)receptor agonists before.~4. Surgical treatment for obesity~5. Past or current chronic or idiopathic pancreatitis, or any of the following: -amylase or lipase above 2 times UNR (upper normal range), triglycerides above 500 mg/dL~6. Have other medical conditions or medical history that make participation in the study unsafe or which may interfere in the interpretation of the results of the study~7. Unwilling to comply with smoking and alcohol restrictions during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- IBI362 (Type: EXPERIMENTAL): Participants received dose 1 level of IBI362 administered as multiple subcutaneous doses.~Participants received dose 2 level of IBI362 administered as multiple subcutaneous doses.~Participants received dose 3 level of IBI362 administered as multiple subcutaneous doses.~Participants received dose 4 level of IBI362 administered as multiple subcutaneous doses.~Participants received dose 5 level of IBI362 administered as multiple subcutaneous doses.
- placebo (Type: PLACEBO_COMPARATOR): Participants received matching placebo dose regiments by subcutaneous injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A New Mouthwash on Reducing Dental Plaque and Helping Prevent Gum Problems

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects, ages 18-70, inclusive.~* Availability for the six-month duration of the clinical research study.~* Good general health.~* Initial gingivitis index of at least 1.0 as determined by the use of the Loe-Silness Gingival Index.~* Initial plaque index of at least 1.5 as determined by the use of the Quigley-Hein Plaque Index.~* Signed Informed Consent Form~Exclusion Criteria:~* Presence of orthodontic bands.~* Tumor(s) of the soft or hard tissues of the oral cavity.~* Advanced periodontal disease (purulent exudate, tooth mobility, and/or extensive loss of periodontal attachment or alveolar bone).~* Five or more carious lesions requiring immediate restorative treatment.~* Antibiotic use any time during the one-month period prior to entry into the study.~* Participation in any other clinical study or test panel within the one month prior to entry into the study.~* Dental prophylaxis during the past two weeks prior to baseline examinations.~* History of allergies to oral care/personal care consumer products or their ingredients.~* On any prescription medicines that might interfere with the study outcome.~* An existing medical condition that prohibits eating or drinking for periods up to 4 hours.~* History of alcohol or drug abuse.~* Self-reported pregnant or lactating subjects

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- 0.2% zinc lactate, 0.17% amine fluoride and 0.0275% sodium fluoride Mouthwash (Type: EXPERIMENTAL): mouthwash
- 0.057% sodium fluoride Mouthwash (Type: ACTIVE_COMPARATOR): mouthwash

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Bimatoprost 0.01% in the Clinical Setting

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of primary open-angle glaucoma or ocular hypertension~* Determined by the treating physician to require treatment with bimatoprost 0.01%.~Exclusion Criteria:~* Previous use of Lumigan® 0.01%

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pts with POAG or OH (Previously Treatment Naive) (Type: None): Previously treatment naïve patients with Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH) who require treatment with bimatoprost 0.01% (Lumigan® 0.01%).
- Pts with POAG or OH (Switched Monotherapy) (Type: None): Patients previously on another monotherapy treatment with Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH) who require treatment with bimatoprost 0.01% (Lumigan® 0.01%).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus Who Have Not Previously Received Anti-Hyperglycemic Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, \>/=18 years of age~* Diagnosis of diabetes mellitus, type 2 within 12 months prior to screening~* Patients who have not received a anti-hyperglycemic medication for at least 12 weeks prior to screening and for not longer than 3 consecutive months in the past~* HbA1c \>/=7% and \</=9.5% at screening or within 4 weeks prior to screening and at pre-randomization visit~* Fasting plasma glucose \</=240 mg/dL at pre-randomization visit~* Agreement to maintain diet and exercise habits during the study~Exclusion Criteria:~* Patients with Type 1 diabetes mellitus, secondary diabetes, diabetes resulting from pancreatic injury, or acute metabolic diabetic complications within the past 6 months~* Any previous treatment with thiazolidinedione or a dual peroxisome proliferator activated receptor (PPAR) agonist~* Any body weight lowering or lipoprotein-modifying therapy within 12 weeks prior to screening (except stable dose of statin)~* Symptomatic congestive heart failure classified as New York Heart Association class II-IV at screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- aleglitazar (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete